

DISCUSSIONS WITH LEADERS

- 499 Advancing Neuroimaging: Julie Price Talks with Henryk Barthel About Enhanced Understanding of the Brain and Neurodegeneration**
Julie C. Price and Henryk Barthel

STATE OF THE ART

- 502 The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease**
Amar U. Kishan, Shankar Siva, Michael S. Hofman, James Nagarajah, Ana P. Kiess, Phuoc Tran, and Jeremie Calais

IS IT REALLY HAPPENING?

- 510 Is ¹⁸F-FDG Metabolic Tumor Volume in Lymphoma Really Happening?**
Sally F. Barrington, Anne-Ségolène Cottreau, and José M. Zijlstra

ONCOLOGY

Clinical

- 512 ⁶⁸Ga-FAPI PET/CT as an Alternative to ¹⁸F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma**
Ertan Sahin, Tulay Kus, Alper Aytekin, Evren Uzun, Umut Elboga, Latif Yilmaz, Yusuf B. Cayirli, Merve Okuyan, Vuslat Cimen, and Ufuk Cimen
- 520 An ¹⁸F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy**
Maria Thor, Chen Lee, Lian Sun, Purvi Patel, Aditya Apte, Milan Grkovski, Annemarie F. Shepherd, Daphna Y. Gelblum, Abraham J. Wu, Charles B. Simone II, et al.
- 527 ⁶⁸Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression**
Chongjiao Li, Qiongrong Chen, Yueli Tian, Jie Chen, Kui Xu, Zhiwei Xiao, Juan Zhong, Jianyuan Wu, Bing Wen, and Yong He

Basic

- 533 Efficacy of [⁶⁷Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2-Positive Neuroendocrine Tumors**
Fabrice Ngoh Njotu, Jessica Pougoue Ketchemen, Anjong Florence Tikum, Hanan Babeker, Brian D. Gray, Koon Y. Pak, Maruti Uppalapati, and Humphrey Fonge

THERANOSTICS

Clinical

- 540 ■ EDITORIAL. PSMA PET AUC Updates: Inclusion of rh-PSMA-7.3**
Thomas A. Hope and Hossein Jadvar

- 541 The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of ²²³Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients**
Dianne Bosch, Kim J.M. van der Velden, Irma M. Oving, Dirk N.J. Wyndaele, Leo E. Weijs, W. Dick van Schelven, Wim J.G. Oyen, Erik T. te Beek, Addy C.M. van de Luijngaarden, Diederik M. Somford, et al.

- 548 Strong Correlation Between SUV_{max} on PSMA PET/CT and Numeric Drop-In γ -Probe Signal for Intraoperative Identification of Prostate Cancer Lesions**
Anne-Claire Berrens, Malou A. Sorbi, Maarten L. Donswijk, Hilda A. de Barros, Samaneh Azorgashasb, Matthias N. van Oosterom, Daphne D.D. Rietbergen, Elise M. Bekers, Henk G. van der Poel, Fijs W.B. van Leeuwen, et al.

- 555 The Value of ⁶⁸Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study**
Jingyan Shi, Danyan Li, Mengxia Chen, Yao Fu, Shan Peng, Qing Zhang, Jing Liang, Qun Lu, Jiaming Lu, Shuyue Ai, et al.

- 560 Prognostic Performance of RECIP 1.0 Based on [¹⁸F]PSMA-1007 PET in Prostate Cancer Patients Treated with [¹⁷⁷Lu]Lu-PSMA I&T**
Philipp E. Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, Hubert Kübler, Sebastian E. Serfling, Takahiro Higuchi, Wiebke Schlötelburg, Kerstin Michalski, Andrei Gafita, Steven P. Rowe, et al.

- 566 Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [¹⁷⁷Lu]Lu-PSMA-617 Therapy**
Deni Hardiansyah, Elham Yousefzadeh-Nowshahr, Felix Kind, Ambros J. Beer, Juri Ruf, Gerhard Glatting, and Michael Mix

- 573 Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study**
Christopher Eigler, Lisa McDougall, Andreas Bauman, Peter Bernhardt, Michael Hentschel, Kristine A. Blackham, Guillaume Nicolas, Melpomeni Fani, Damian Wild, and Dominik Cordier

Basic

- 580 ■ FEATURED BASIC SCIENCE ARTICLE. Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer**
Kyeara N. Mack, Zachary V. Samuels, Lukas M. Carter, Tara D. Viray, Komal Mandleywala, Cory L. Brooks, Michael A. Hollingsworth, Prakash Radhakrishnan, and Jason S. Lewis

- 586 Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma**
Fanching Lin, Renee Clift, Takeru Ehara, Hayato Yanagida, Steven Horton, Alain Noncovich, Matt Guest, Daniel Kim, Katrina Salvador, Samantha Richardson, et al.

593 Development and Preclinical Evaluation of [²¹¹At]PSA-3-Ga: An Inhibitor for Targeted α -Therapy of Prostate Cancer

Mohamed El Fakiri, Nawal Ayada, Marius Müller, Lars Hvass, Teodor H. Gamzov, Anne Skovsbo Clausen, Nicolas M. Geis, Nils Steinacker, Ellinor Hansson, Sture Lindgren, et al.

NEUROLOGY

Clinical

600 Can Internal Carotid Arteries Be Used for Noninvasive Quantification of Brain PET Studies?

Laura Providência, Chris W.J. van der Weijden, Philipp Mohr, Joyce van Sluis, Johannes H. van Snick, Riemer H.J.A. Slart, Rudi A.J.O. Dierckx, Adriaan A. Lammertsma, and Charalampos Tsoumpas

CARDIOVASCULAR

Clinical

607 ■ SPECIAL CONTRIBUTION. Total-Body PET/CT Applications in Cardiovascular Diseases: A Perspective Document of the SNMMI Cardiovascular Council

Riemer H.J.A. Slart, Frank M. Bengel, Cigdem Akincioglu, Jamieson M. Bourque, Wengen Chen, Marc R. Dweck, Marcus Hacker, Saurabh Malhotra, Edward J. Miller, Matthieu Pelletier-Galarneau, et al.

PULMONARY

Clinical

617 [¹⁸F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung Diseases

Joanna C. Porter, Balaji Ganeshan, Thida Win, Francesco Fraioli, Saif Khan, Manuel Rodriguez-Justo, Raymond Endozo, Robert I. Shortman, Luke R. Hoy, Toby M. Maher, et al.

AI/ADVANCED IMAGE ANALYSIS

Clinical

623 Clinical Evaluation of Deep Learning for Tumor Delineation on ¹⁸F-FDG PET/CT of Head and Neck Cancer

David G. Kovacs, Claes N. Ladefoged, Kim F. Andersen, Jane M. Brittain, Charlotte B. Christensen, Danijela Dejanovic, Naja L. Hansen, Annika Loft, Jørgen H. Petersen, Michala Reichkender, et al.

630 PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non-Small Cell Lung Cancer Treated with Curative Radiotherapy

Vincent Bourbonne, Moncef Morjani, Olivier Pradier, Mathieu Hatt, Vincent Jaouen, Solène Querellou, Dimitris Visvikis, François Lucia, and Ulrike Schick

635 Promising Candidate Prognostic Biomarkers in [¹⁸F]FDG PET Images: Evaluation in Independent Cohorts of Non-Small Cell Lung Cancer Patients

Narinée Hovhannisyani-Baghdasarian, Marie Luporsi, Nicolas Captier, Christophe Nioche, Vesna Cuplov, Erwin Woff, Nadia Hegarat, Alain Livartowski, Nicolas Girard, Irène Buvat, et al.

643 Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT

Kevin H. Leung, Steven P. Rowe, Moe S. Sadaghiani, Jeffrey P. Leal, Esther Mena, Peter L. Choyke, Yong Du, and Martin G. Pomper

PHYSICS AND INSTRUMENTATION

652 Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the National Electrical Manufacturers Association NU 2-2018 Standard

Guiyu Li, Wenhui Ma, Xiang Li, Weidong Yang, Zhiyong Quan, Taoqi Ma, Junling Wang, Yunya Wang, Fei Kang, and Jing Wang

SPECIAL CONTRIBUTION

659 The Accomplishments and Legacy of Saul Hertz, MD

Bennett S. Greenspan, Michael S. Hofman, and John Buscombe

THE ILLUSTRATED POST

664 ■ FEATURED ARTICLE OF THE MONTH. First-in-Human ²¹²Pb-PSMA-Targeted α -Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer

Matthew R. Griffiths, David A. Pattison, Melissa Latter, Kevin Kuan, Stephen Taylor, William Tieu, Thomas Kryza, Danielle Meyrick, Boon Quan Lee, Aaron Hansen, et al.

665 Imaging PARP Upregulation with [¹²³I]-PARPi SPECT/CT in Small Cell Neuroendocrine Carcinoma

Honest Ndlovu, Ismaheel Lawal, Kgomotso Mokoala, Dineo Disenyane, Nonhlahla Nkambule, Sheynaz Bassa, Yonwaba Mzizi, Meshack Bida, and Mike Sathekge

DEPARTMENTS

8A This Month in JNM

650 Errata